Photodynamic quenched cathepsin activity based probes for cancer detection and macrophage targeted therapy

Theranostics

Volumn 5, Issue 8, 2015, Pages 847-862

  Ben Nun, Yael ^a   Merquiol, Emmanuelle ^a   Brandis, Alexander ^b   Turk, Boris ^c,d,e   Scherz, Avigdor ^b   Blum, Galia ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c JO EF STEFAN INSTITUTE   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

^e Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins   (Slovenia)

Author keywords

Activity based probes; Cathepsins; Macrophages; Non invasive imaging; Photodynamic therapy

Indexed keywords

2,6 DIMETHYL THEREPHTHALIC AMIDE 6 AMINOHEXANE; CATHEPSIN B; CATHEPSIN L; CATHEPSIN S; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; BACTERIOCHLORIN; CATHEPSIN; PORPHYRIN;

ACTIVITY BASED PROBE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BREAST CANCER; CANCER DIAGNOSIS; CELL KILLING; CONTROLLED STUDY; DRUG SYNTHESIS; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOLECULAR PROBE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHOTOCHEMICAL QUENCHING; PHOTODYNAMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; BAGG ALBINO MOUSE; IMMUNOLOGY; LIGHT; METABOLISM; NEOPLASMS, EXPERIMENTAL; PHOTOTHERAPY; PROCEDURES; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; THERANOSTIC NANOMEDICINE;

ANIMALS; CATHEPSINS; LIGHT; MACROPHAGES; MALE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; PHOTOSENSITIZING AGENTS; PHOTOTHERAPY; PORPHYRINS; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; THERANOSTIC NANOMEDICINE;

EID: 84941312661     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.10854     Document Type: Article

References (41)

1. Turk V, Turk B, Turk D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 2001;20(17):4629-33.
2. Jedeszko C, Sloane BF. Cysteine cathepsins in human cancer. Biol Chem. 2004;385(11):1017-27.
3. Jagodic M, Vrhovec I, Borstnar S, et al. Prognostic and predictive value of cathepsins D and L in operable breast cancer patients. Neoplasma. 2005;52(1):1-9.
4. Harbeck N, Alt U, Berger U, et al. Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy. Clin Cancer Res. 2001;7(9):2757-64.
5. Lah TT, Cercek M, Blejec A, et al. Cathepsin B, a prognostic indicator in lymph node-negative breast carcinoma patients: comparison with cathepsin D, cathepsin L, and other clinical indicators. Clin Cancer Res. 2000;6(2):578-84.
6. Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006;20(5):543-56.
7. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5(5):443-53.
8. Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6(9):594-602.
9. Shree T, Olson OC, Elie BT, et al. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011;25(23):2465-79.
10. Salpeter SJ, Pozniak Y, Merquiol E, et al. A novel cysteine cathepsin inhibitor yields macrophage cell death and mammary tumor regression. Oncogene. 2015; 23: 51.
11. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454(7203):436-44.
12. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71-8.
13. Joyce JG, ter Meulen J. Pushing the envelope on HIV-1 neutralization. Nat Biotechnol. 2010;28(9):929-31.
14. Zhang Y, Cheng S, Zhang M, et al. High-infiltration of tumor-associated macrophages predicts unfavorable clinical outcome for node-negative breast cancer. PLoS One. 2013;8(9):e76147.
15. Kahlenberg JM, Dubyak GR. Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ release. Am J Physiol Cell Physiol. 2004;286(5):C1100-8.
16. Edgington LE, Verdoes M, Ortega A, et al. Functional imaging of legumain in cancer using a new quenched activity-based probe. J Am Chem Soc. 2013;135(1):174-82.
17. Hu M, Li L, Wu H, et al. Multicolor, one-and two-photon imaging of enzymatic activities in live cells with fluorescently Quenched Activity-Based Probes (qABPs). J Am Chem Soc. 2011;133(31):12009-20.
18. Sellars JD, Landrum M, Congreve A, et al. Fluorescence quenched quinone methide based activity probes-a cautionary tale. Org Biomol Chem. 2010;8(7):1610-8.
19. Blum G, Weimer RM, Edgington LE, et al. Comparative Assessment of Substrates and Activity Based Probes as Tools for Non-Invasive Optical Imaging of Cysteine Protease Activity. PLoS One. 2009;4(7):e6374.
20. Blum G, von Degenfeld G, Merchant MJ, et al. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes. Nat Chem Biol. 2007;3(10):668-77.
21. Blum G, Mullins SR, Keren K, et al. Dynamic imaging of protease activity with fluorescently quenched activity-based probes. Nat Chem Biol. 2005;1(4):203-9.
22. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic Therapy. J Natl Cancer Inst. 1998;90(12):889-905.
23. Klara S, Juan C, Gang Z. Killer Beacons for Combined Cancer Imaging and Therapy. Curr Med Chem. 2007;14(20):2110-25.
24. Wiseman H, Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313 (Pt 1):17-29.
25. Albert W G. New trends in photobiology: Photosensitized oxidation of cholesterol in biological systems: Reaction pathways, cytotoxic effects and defense mechanisms. J Photochem Photobiol B. 1992;13(2):105-18.
26. Piette J. Mutagenic and genotoxic properties of singlet oxygen. J Photochem Photobiol B. 1990;4(3):335-9.
27. Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J Porphyr Phthalocyanines. 2001; 5: 105-29.
28. Primbs GB, Casey R, Wamser K, et al. Photodynamic therapy for corneal neovascularization. Ophthalmic Surg Lasers. 1998;29(10):832-8.
29. Mang TS, Allison R, Hewson G, et al. A phase II/III clinical study of tin ethyl etiopurpurin (Purlytin)-induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer. Cancer J Sci Am. 1998;4(6):378-84.
30. Hu HY, Vats D, Vizovisek M, et al. In vivo imaging of mouse tumors by a lipidated cathepsin S substrate. Angew Chem Int Ed Engl. 2014;53(29):7669-73.
31. Brandis A, Mazor O, Neumark E, et al. Novel Water-soluble Bacteriochlorophyll Derivatives for Vascular-targeted Photodynamic Therapy: Synthesis, Solubility, Phototoxicity and the Effect of Serum Proteins. Photochem Photobiol. 2005;81(4):983-93.
32. Rozman J, Stojan J, Kuhelj R, et al. Autocatalytic processing of recombinant human procathepsin B is a bimolecular process. FEBS Lett. 1999;459(3):358-62.
33. Bromme D, Nallaseth FS, Turk B. Production and activation of recombinant papain-like cysteine proteases. Methods. 2004;32(2):199-206.
34. Mihelic M, Dobersek A, Guncar G, et al. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation. J Biol Chem. 2008;283(21):14453-60.
35. Kato D, Boatright KM, Berger AB, et al. Activity-based probes that target diverse cysteine protease families. Nat Chem Biol. 2005;1(1):33-8.
36. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006;5(9):785-99.
37. Shon SM, Choi Y, Kim JY, et al. Photodynamic therapy using a protease-mediated theranostic agent reduces cathepsin-B activity in mouse atheromata in vivo. Arterioscler Thromb Vasc Biol. 2013;33(6):1360-5.
38. Choi Y, Weissleder R, Tung CH. Selective antitumor effect of novel protease-mediated photodynamic agent. Cancer Res. 2006;66(14):7225-9.
39. Zheng G, Chen J, Stefflova K, et al. Photodynamic molecular beacon as an activatable photosensitizer based on protease-controlled singlet oxygen quenching and activation. Proc Natl Acad Sci U S A. 2007;104(21):8989-94.
40. Stefflova K, Chen J, Li H, et al. Targeted photodynamic therapy agent with a built-in apoptosis sensor for in vivo near-infrared imaging of tumor apoptosis triggered by its photosensitization in situ. Mol Imaging. 2006;5(4):520-32.
41. Goldshaid L, Rubinstein E, Brandis A, et al. Novel design principles enable specific targeting of imaging and therapeutic agents to necrotic domains in breast tumors. Breast Cancer Res. 2010;12(3):R29.